Marsi Bionics is a Spanish project dedicated to the design, development, and commercialization of patented robotic exoskeletons with variable joints to improve human walking. Currently, this SME is immersed in a round of funding through Fellow Funders which aims to obtain one and a half million euros. Are there reasons to make such an outlay on this project?
The answer is yes. There are at least 213,000 reasons, that is, the number of patients who could benefit from the use of the Marsi exoskeletons. This number represents only the exoskeletons that are already on the market, to which the company intends to add the Stelo model in the near future. Currently, Marsi Bionics has a presence in the market thanks to its MAK Active Knee and Atlas Pediatric Exo robots.
The MAK Active Knee has application in rehabilitation after total knee arthroplasty, reducing rehabilitation time by 66%. It can also be used in rehabilitation after strokes and neuromuscular diseases such as multiple sclerosis, dystrophies, or muscular atrophy. All of these conditions affect up to 195,000 people in Spain. This figure rises to almost two million patients in Europe, and to more than 32 million on the planet.
The first exoskeleton for children
The Pediatric Exo Atlas, on the other hand, has a smaller but more vulnerable target audience: children. This model is designed for children between four and ten years old with diseases such as cerebral palsy, spinal cord injury, spinal muscular atrophy, and myopathies. The sum of these diseases affects more than 18,000 people in Spain, and more than 131,000 people in Europe.
The Pediatric Exo Atlas has turned Marsi Bionics into a pioneering startup in the world of pediatrics, being the first to create a child exoskeleton in the world. The exoskeleton allows patients to walk, perform certain movements and helps them increase their muscle capacity by 200%, avoiding derived complications from the disease and increasing their life expectancy.
Both exoskeletons, the MAK Active Knee, and the Atlas Pediatric Exo, have a great relevance in the treatment of patients with neuromuscular diseases. While the MAK Active Knee has a large target audience, the Atlas Pediatric Exo has been a turning point for children, who suffer these diseases from the early stages of their lives and need tools that allow them to have a normal and happy life.
Stelo, the next one
By 2022, Marsi Bionics is expected to launch its new model, Stelo. It will target patients with brain damage, Parkinson’s, spinal cord injury, and amyotrophic lateral sclerosis. This group of diseases affect a large sector of the population. Therefore, many patients will benefit from Marsi’s advances.
Undoubtedly, Marsi Bionics represents an ESG investment that improves the lives of many patients and their families. Nowadays it is not known how to eradicate muscle and brain diseases, but companies like Marsi help to alleviate their effects. At Fellow Funders, we are proud to support projects like this one that, beyond the business results, represent a great benefit to society